Humanetics

Humanetics is a leading biotechnology company based in Eden Prairie, MN, specializing in the development of innovative treatments for solid tumor cancer, inflammatory lung diseases, and biodefense. With a focus on improving patient outcomes, their cutting-edge technology, BIO300, has shown promising results in limiting inflammation and fibrosis caused by viral infections, enhancing the efficacy of radiotherapy against lung tumors, and preventing and mitigating acute and delayed radiation injuries. Through collaborations with key partners and a strong intellectual property portfolio, Humanetics is dedicated to advancing the field of oncology and protecting civilians, first responders, and the military from nuclear accidents and acts of terrorism.

With a team of experienced leaders and experts in the field, including renowned medical professionals and scientists, Humanetics has achieved significant milestones in the development of BIO300. Their positive clinical trial results in patients with non-small cell lung cancer and the FDA approval for studies in a second oncology indication demonstrate the potential of their technology. Committed to continuous research and development, Humanetics has received funding from prestigious organizations like the Department of Defense and has published numerous publications showcasing the safety, mechanism of action, and pharmacokinetics of BIO300. As a forward-thinking biotech company, Humanetics is dedicated to improving patient outcomes and making a significant impact in the field of cancer treatment and biodefense.

Generated from the website